Abstract BACKGROUND: Patients with Psychotic Depression (PD) exhibit elevated cortisol levels.
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INTRODUCTION
Psychotic depression (PD) is a severe form of major depression characterized by delusions and/or hallucinations and has a prevalence rate of 0.3-0.4%.(1),(2) PD is associated with higher mortality than non-psychotic depression due to more frequent suicide attempts (often by violent means), as well as increased all-cause mortality. (3) Hypercortisolism distinguishes PD from other depressive subtypes (4) , (5), (6) , (7), (8) as indicated by: elevated levels of urinary free cortisol,(5) elevated serum adrenocorticotropic hormone (ACTH) and cortisol levels, (6) and high rates of non-suppression on challenge with dexamethasone and high post-dexamethasone serum cortisol levels. (7), (8) One hypothesis suggests that elevated cortisol in patients with PD leads to overstimulation of the glucocorticoid receptor (GR), which stimulates the glucocorticoid responsive elements that control dopamine and glutamate leading to psychosis in susceptible individuals. (9) There are no FDA approved treatments for PD despite its high rate of mortality and morbidity. Standard of care treatment for PD includes electroconvulsive therapy (ECT) or combination antidepressant/antipsychotic therapy, despite limited supporting controlled study results.
Placebo response rates in psychopharmacologic studies have steadily increased over the past three decades, significantly hampering development of new therapies. (10) , (11) While earlier studies in PD reported relatively low placebo response rates, studies over the past decade have reported significantly higher rates of response to placebo. (12) , (13) In 1985, Schatzberg (9) proposed that reducing the effects of cortisol (by lowering cortisol levels or antagonizing cortisol's effects at GR) could decrease psychotic symptoms in patients M A N U S C R I P T
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T. Block 5 with psychotic depression. Belanoff et al (14) observed that antagonism of GR with four-day administration of mifepristone (a potent competitive GR antagonist) under double-blind, placebo-controlled crossover conditions, rapidly and durably reversed the psychotic symptoms of PD in a small number of patients. Subsequently, a number of open label and double-blind trials have been conducted by both Corcept Therapeutics and independent researchers. (13) , (15) , (16) , (17) , (18) , (19) , (20) , (21) In all studies, mifepristone has produced response rates numerically superior to placebo; however, statistical significance has been less consistently observed. GR antagonism with mifepristone leads to significant increases in plasma ACTH and serum cortisol through inhibition of negative feedback loops in the hypothalamicpituitary-adrenal (HPA) system.(17) Higher plasma levels of mifepristone are associated with more robust changes to ACTH and cortisol. (21) In one small pilot study, increases in cortisol after one week of treatment were associated with improvement in psychosis several weeks later.(15) All of the trials have been published previously (13) , (17) , (18) , (20) , (21) and four were reviewed recently by Schatzberg.
We provide a combined analysis of the five similarly designed double-blind Phase 2/3 studies of mifepristone to treat PD sponsored by Corcept Therapeutics. The composite data from these studies in patients with PD (mifepristone n=833, placebo n=627) indicate that seven days of treatment with mifepristone can reduce the psychotic symptoms of PD for periods up to eight weeks, and is both safe and well tolerated. Moreover, data indicate that the Day 7 therapeutic mifepristone plasma level (≥ 1637 ng/mL) and two mediators demonstrating the extent of GR antagonism, post-treatment increased adrenocorticotropin hormone (ACTH) levels and cortisol, have a strong association with treated patients' reduction in psychotic symptoms.
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METHODS AND MATERIALS
General Study Design
Patients with PD were randomized to seven days of double-blind treatment with mifepristone or placebo. Entry criteria for four of the five studies (Study 1 was the exception) also included a minimum derived baseline BPRS positive symptom subscale (PSS) of 8 or above.
An FDA approved antidepressant was administered for seven or eight weeks of the eight week trials. Patients enrolled to these studies had not been taking antidepressants or antipsychotics for 7 days (30 days for fluoxetine) prior to enrollment. Mifepristone doses varied across studies; they were 300 mg, 600 mg, or 1200 mg per day. All patients signed informed consent and 4 out of 5 studies (Study 1 prior to Regulations) were listed in www.clinicaltrials.gov.
Combined Analyses
The combined analysis of data from these five separate studies uses one set of consistent statistical methods, based on an a priori-defined statistical analysis plan.
Efficacy Measurements
For all five studies, efficacy was measured using the overall 18 item BPRS score, the 4-item PSS of the BPRS, and the 24-item Hamilton Depression Rating Scale (HDRS). The PSS subscale, the primary scale for these analyses, is derived by summing the ratings across all 4 items (conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content) and subtracting 4 because absence of a symptom is designated as 1 on the scale. This is consistent with the previous reporting of all efficacy analyses.
The primary endpoint in all studies was the proportion of patients with ≥ 50% reduction from baseline on the BPRS-PSS. All studies used the ITT (intent-to-treat) population as the basis for all primary analyses. All subjects needed at least one post-baseline BPRS measurement M A N U S C R I P T
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T. Block 8 trials 1, 2, and 4. This ROC approach identified the mifepristone plasma threshold of 1637 ng/mL as optimal for discriminating responders from non-responders with the greatest specificity and sensitivity. A mifepristone plasma level ≥ 1637 ng/mL is defined High-PL (high plasma level) and below 1637 ng/mL is defined as Low-PL (low plasma level). This plasma mifepristone threshold of 1637 ng/mL was first selected as an a priori endpoint and applied to Study 5, and was then later selected a priori for this combined analysis. Cortisol and ACTH levels were obtained in all studies at baseline and Day 7, and measured by radioimmunoassay (RIA). Because the cortisol and ACTH measurements were analyzed by different labs for different studies, their percentage change rather than their absolute change was calculated in order to standardize across studies.
Statistical Analyses
Data from all five studies were available for statistical analysis, representing mifepristone doses of 300 mg (n=110), 600 mg (n=471), 1200 mg (n=252), and placebo (n=627). Results are presented by all-doses-combined (300 mg + 600 mg + 1200 mg, n= 833) vs placebo (n=627), by individual dose vs. placebo, and by groups above and below the mifepristone plasma level threshold of 1637 ng/mL. Patients with insufficient baseline PSS scores from Study 1 (n=72)
were removed from analysis, leading to an ITT efficacy sample size of n=1388 (mifepristone n=793, placebo n=595).
An a priori statistical analysis plan was implemented for the combined analysis of the 1,388 patients described above. Analysis of the primary efficacy endpoint utilized a Fisher's exact test to compare proportions, and a 95% CI to compare differences in two binomial
proportions. Analysis of continuous measures of efficacy including the BPRS-PSS % change from baseline and the HAMD Total Score % change from baseline to subsequent study visit is
based on a mixed model repeated measures (MMRM) analysis of covariance in which treatment and visit are fixed effects, intercept and subject are random effects, and a treatment by visit interaction term, with the baseline value as a covariate, was included. The 95% CI for differences in least square means are presented in forest plots. For interpretation of clinical relevance, the number needed to treat (NNT) was calculated for the primary efficacy endpoint.
The NNT analysis was conducted for both High-PL and Low-PL groups of patients. The number needed to harm (NNH) was calculated using dropouts due to adverse effects. Effect size based on two independent samples was used. Cohen's d effect size descriptors are applicable herein.
(22) All analyses were performed using SAS version 9.2. A p-value of ≤0.05 is determined to be statistically significant.
RESULTS
Combined Analysis (Studies 1-5)
The baseline characteristics of the n=1,460 patients are summarized in Table 1 (mifepristone 833; placebo 627). No statistically significant differences in baseline characteristics were identified.
Dropout rates were 18.5% and 19.2% for the patient groups who received mifepristone and placebo, respectively. The primary efficacy analyses for all ITT patients (n=1388; mifepristone 793, placebo 595), independent of plasma level, indicated mifepristone separated significantly from placebo on the primary endpoint (mifepristone 36.8%, placebo 28.5%; p=0.004) ( Table 2 ).
In Table S1 , the percentage changes from baseline in BPRS-PSS by visit (Weeks 1, 2, 4, and 8) indicate significant separation of drug over placebo by Week 2 and continuing through Week 8. The 95% CI for the mean differences from placebo are displayed in Figure 1 .
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
T. Block 10 To assess the clinical relevance of mifepristone plasma level, the NNT for meeting response criteria on the BPRS-PSS was calculated by plasma level group. Table 3 with mifepristone plasma level ≥ 1637 ng/mL are referred to as High-PL and < 1637 ng/mL as Low-PL. As indicated in Table 3 , an NNT of 7 was observed in the High-PL mifepristonetreated group, compared to an NNT of 48 in the Low-PL mifepristone-treated group. Combined (High-PL plus Low-PL) demonstrated an NNT of 12 when compared to placebo. In the High-PL group, the NNTs for each dose tested (300, 600, or 1200 mg/d) were 7, 8, and 8,respectively.
Although mifepristone does not have linear pharmacokinetics, higher doses do yield higher plasma levels which plateau at doses greater than 1200 mg. Mifepristone plasma levels ≥ 1637 ng/mL were found in 25% (24/97) of the 300 mg/d group, 44% (173/396) of the 600 mg/d group, and 65% (146/225) of the 1200 mg/d group.
The magnitude of change from baseline in Day 7 ACTH and cortisol levels was significantly correlated with Day 7 mifepristone plasma level; the correlation was stronger for cortisol (r=0.30, p<0.0001, n=670) than it was for ACTH (r=0.19, p<0.0001, n=646). The change in ACTH significantly and strongly correlated with the change in cortisol levels (using logarithms, Pearson r=0.47, p<0.0001, n=655).
In Figure 1 and Table 4 , the High-PL group demonstrated significantly increased response rates on the primary efficacy variable (p=0.0004), as well as in their increases in Day 7
ACTH and cortisol values, compared to the Low-PL and placebo group. The high plasma level group's significantly greater increase in ACTH and cortisol (Table 4) demonstrates an increased M A N U S C R I P T
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We assessed the relative effects of mifepristone versus placebo on symptoms of depression as measured by HDRS scores. As indicated in Figure 2 , mifepristone separated significantly from placebo on 50% reduction in HDRS from baseline at weeks 4 and 8 only in only those patients who attained the therapeutic blood level (High-PL). In Table S2 we present analyses of percentage change from baseline in HDRS by individual study day and by plasma level group.
We conducted an analysis of the relative mediation effects of ACTH, cortisol, and plasma level of drug as detailed in Figure 3 . Path A represents the change in plasma ACTH and cortisol levels on Day 7, based on the effect of treatment with mifepristone. Path B represents a weaker association between change in both ACTH and cortisol levels on Day 7 and reduction in psychotic symptoms up to eight weeks. Path C, the mifepristone plasma level, represents the strongest association observed with response, as measured by reduction in psychosis. The difference between the High-PL and Low-PL groups on response is seen in Table 4 and Figures 1 and 2. We also show the differences between the two groups in the five studies in Table 3 .
Safety
Adverse events from all five studies (n=1,460) were evaluated by dose group and by all doses combined. Treatment emergent adverse events (TEAEs) were reported in 556 (66.7%) mifepristone treated patients and 386 (61.6%) placebo treated patients. There were three deaths reported; two patients who received mifepristone and one patient who received placebo. More detailed adverse event descriptions are listed below in Table 5 .
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T. Block 12 Overall, the safety of mifepristone versus placebo was comparable, with a similar number of events noted in each group. The Number Needed to Harm (NNH) was calculated using the outcome of study dropouts due to adverse events. For all studies combined, the NNH for mifepristone was incalculable because dropouts due to side effects were higher for placebo (1.6%) than for mifepristone (1.4%). In two studies, dropouts because of adverse events were higher for mifepristone than placebo (1.0% vs 0.9%, NNH=1,000 in Study 1 and 2.4% vs 1.6%, NNH=126 in Study 3). Mifepristone appeared safe and well tolerated across all three dosage groups. The rates of TEAEs were similar across placebo (62%), mifepristone total (67%), mifepristone High-PL (69%), and mifepristone Low-PL (65%) groups. There was no statistically significant difference in rates of AEs between mifepristone High-PL and Low-PL groups. Higher than anticipated placebo response were observed in studies 2-5, consistent with the unfortunate trend noted in studies of many psychiatric indications. (10), (11), (23) . However, there may be additional contributing factors to the high placebo response rates in these studies.
DISCUSSION
For one, estimates of placebo response rates from early PD studies were derived largely from single-blind studies, possibly underestimating the true double-blind placebo response rates.
Second, many of the patients enrolled in the five studies reported here were recruited as outpatients but hospitalized as required by protocol, potentially introducing non-specific treatment effects.(12) Posener et al (6) reported that in patients with PD (but not in control subjects) cortisol levels decline during hospitalization. Third, earlier literature suggested that tricyclic antidepressants alone were less effective in the treatment of PD that in non-psychotic depression, a view challenged by a more recent study evaluating SSRI monotherapy in PD. (24) In these five studies, all patients received an FDA approved antidepressant for seven or eight weeks of the eight-week trials.
A minimum PSS score of 12, indicating at least moderate levels of psychosis, was required for study entry. This could have led to baseline score inflation. A high response rate at Week 1 is in keeping with score inflation at baseline. Arguing against this is Study 5, which M A N U S C R I P T
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Despite high placebo response rates observed in the individual studies, the combined analysis of all mifepristone treated patients separated from placebo treated patients with statistical significance on the primary endpoints, and this effect was further accentuated when incorporating the a priori-defined therapeutic mifepristone plasma level of 1637 ng/mL. The ROC methodology used to determine the cutpoint between High-PL and Low-PL is a statistical analysis that seeks to optimize the discrimination (ie, sensitivity and specificity) between responders and not-responders, and hence the cutpoint is a statistical value rather than a biological value. Figure 1 demonstrates that in this combined analysis of 5 studies, the mifepristone High-PL group separates strongly from the placebo treated group on the primary efficacy endpoint in contrast to the mifepristone Low-PL group which did not. Results were similar for the LOCF and Observed Case analyses. At 1200 mg of mifepristone per day, approximately 65% of subjects attained a therapeutic plasma level of mifepristone.
These statistically significant differences appeared clinically meaningful as evidenced by an overall NNT of 7 in the High-PL mifepristone-treated-patient group. In patients who did not attain the therapeutic mifepristone plasma level, the NNT was 48 indicating a substantially lower treatment effect than the High-PL group. The NNT of 7 for the High-PL group compares favorably to antipsychotic agents approved in the United States, including olanzapine. The data presented indicate that the antipsychotic effect of mifepristone is indeed based on adequate mifepristone plasma level exposure. When results were assessed dividing the overall sample by dose received (300, 600, or 1200 mg/d), similar results were observed, with NNTs of 7 to 8 noted across the three doses. Thus, our data appear to support the hypothesis that seven days of M A N U S C R I P T
T. Block 15 mifepristone, especially at sufficient plasma levels (High-PL), is beneficial in reducing the In addition to low and clinically meaningful NNTs for mifepristone in the studies, the drug appeared to be safe and very well tolerated. Overall dropout rates for any reason were less than 20% in the mifepristone trials as compared to 56% in the olanzapine-fluoxetine (OFC) versus olanzapine (OLZ) trial. (12) In that trial, dropouts due to side effects were 10% for OLZ, 20% for OFC, and 6% for placebo. The NNHs were 25 for olanzapine and 7 for OFC. In the mifepristone combined dataset, dropout rates due to TEAEs were 1.4% in the placebo arm, and 1.2% in the mifepristone arm. In three of the mifepristone studies, placebo dropout rates due to adverse events were numerically larger than were those for mifepristone. NNHs using dropouts M A N U S C R I P T
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When one takes into account the common cardiovascular and metabolic comorbidities that accompany PD (3), the safety profile of medications become especially relevant. The atypical antipsychotic medications commonly used in psychotic disorders can have profound adverse effects on weight and metabolic parameters such as glucose tolerance, and can generate other serious adverse events including tardive dyskinesia. An effective medication that can be given for only seven days to provide a clinical effect lasting up to 56 days with a superior safety profile would be welcome in the field. Administration of mifepristone was not associated with any of the usual side effects seen with atypical antipsychotics.
In summary, a pooled analysis of five studies evaluating the effectiveness of mifepristone in the treatment of the symptoms of psychotic depression demonstrated a reduction in psychosis when compared to placebo, especially at higher mifepristone plasma levels (High-PL), that are best attained using a 1200 mg/d dose. In addition, the use of mifepristone appears safe and well tolerated. Taken together, these data support a high benefit to risk ratio for mifepristone in the treatment of psychotic depression, a serious psychiatric disorder for which there are no FDA approved treatments. M A N U S C R I P T 
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